argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
03 jun 2016 - 07:00
Statutaire naam
argenx SE
Titel
argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111
Bericht
Additional preclinical data support potential of ARGX-111 in targeting tumor microenvironment
Breda, the Netherlands/Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, today announced data published in conjunction with the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting (Chicago, USA) presenting efficacy and safety data from its ARGX-111 Phase 1 expansion study in patients with MET amplified tumors. The data confirm ARGX-111 to have a favorable safety profile and to continue to show signs of anti-tumor activity. The abstract can be accessed here.
Gerelateerde downloads
Datum laatste update: 12 februari 2025